
World-first personalized lung cancer vaccine arrives in Merseyside trial
A 68-year-old Merseyside woman, Chris Jones, has become the first in the world to receive a personalized vaccine for advanced non-small cell lung cancer in an early-stage trial at Clatterbridge Cancer Centre. The vaccine uses DNA derived from her tumour to create a patient-specific immunotherapy, delivered alongside her standard treatment in a seven-dose, 24-week regimen. Researchers hope it boosts the immune response and overcomes resistance to current immunotherapy, with results assessed after six weeks; only 10 participants are taking part in this world-first study led by Professors Ottensmeier and Savelyeva.



